CTMC Company Research Report

Company Overview

Name

CTMC (a joint venture between MD Anderson Cancer Center and Resilience)

Mission of the Company

CTMC's mission is to advance cell therapies from concept to clinical applications to ultimately cure cancer.

Founding

Date Founded: May 2022
Founders: Joint venture between MD Anderson Cancer Center and Resilience

Key People

Jason Bock: Co-Founder + CEO

Houman Mesghali: Co-Founder + COO

Priya Balasubramanian: Head of Quality Control + Analytical Development

Chantale Bernatchez: Head of Process Development

Dan Catron: Head of Corporate Development

Jane Koo: Head of Regulatory Affairs

Laine Linden: Head of Technical Operations

Jose Torres: Head of Quality Assurance

Erin K. Willert: Head of Project + Alliance Leadership

Board Members:

Jason Bock, PhD: Co-Founder + CEO, CTMC

Ferran Prat, JD, PhD: Administration + Industry Relations, MD Anderson

Giulio Draetta, MD, PhD: Senior VP + Chief Scientific Officer, MD Anderson

Rahul Singhvi, ScD, MBA: Co-Founder + CEO, Resilience

Ori Solomon, JD: Executive VP, Chief Legal + Administrative Officer, Resilience

Headquarters

2130 West Holcombe Blvd, Houston, Texas 77030

Number of Employees

93+ industry veterans and academic scientists

Revenue

No information is available

Company Focus

CTMC is known for its pioneering work in cell therapies for cancer, offering a potential single-dose cure for cancer through advanced biopharmaceutical manufacturing technology and leading cancer research.

Products

Product Offerings

CTMC primarily focuses on developing various advanced cell therapies, specifically:

CAR-T (Chimeric Antigen Receptor T-cells)

TIL (Tumor Infiltrating Lymphocytes)

ETC (Engineered T-Cells)

TCR-T (T-Cell Receptor Therapy)

High-Level Description

CTMC provides innovative cell therapy modalities intending to combat cancer effectively. These therapies are developed through rigorous scientific methods and are supported by advanced biopharmaceutical manufacturing technology.

Key Features

Utilizes MD Anderson's leading cancer research capabilities.

Employs 60,000 sq. ft. state-of-the-art manufacturing facilities.

Integration with Resilience’s cloud-based, digital-first electronic systems.

Focused on delivering first-in-human therapies with proof of principle.

Comprehensive process and analytical development for commercialization.

Recent Developments

New Partnerships and Collaborations

1. March Biosciences and CTMC Alliance

Date: September 11, 2023

Goal: Propel innovative cancer cell therapies.

2. KSQ Therapeutics and CTMC Collaboration

Date: September 8, 2023

Goal: Accelerate the development of novel engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies for solid tumors.

New Products Launched and Clinical Data

1. Obsidian Therapeutics’ OBX-115 Engineered TIL Cell Therapy

Announcement Date: December 12, 2023

Development Stage: Positive interim top-line clinical data for advanced or metastatic melanoma post-Anti-PD1 therapy.

Recent Features and Approvals

FDA Approval for Cell Therapy to Treat Melanoma

Date: February 20, 2024

Significance: a watershed moment for cancer therapies, leveraging the body’s own cells as a ‘living drug’.

FDA Nod

FDA Accelerated Approval for Lifileucel

Date: February 16, 2024

Use Case: For unresectable, metastatic melanoma.

Engineering and Regulatory Announcements

Collaboration with Ori Biotech

Date: September 15, 2022

Focus: Automated cell and gene therapy manufacturing.

Conclusion

This report consolidates the critical components of CTMC, accentuating its strategic partnerships, state-of-the-art facilities, and focus on pioneering cancer therapies. Through its robust integration of cutting-edge biopharmaceutical manufacturing and cancer research, CTMC is set to make significant strides in bringing lifesaving treatments to patients efficiently.

For more information, contact: